Xbrane Biopharma (Sweden) Price Prediction
| XBRANE Stock | SEK 0.18 0.01 5.26% |
Oversold Vs Overbought
44
Oversold | Overbought |
Using Xbrane Biopharma hype-based prediction, you can estimate the value of Xbrane Biopharma AB from the perspective of Xbrane Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Xbrane Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Xbrane because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Xbrane Biopharma after-hype prediction price | SEK 0.18 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Xbrane |
Xbrane Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Xbrane Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Xbrane Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Xbrane Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Xbrane Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Xbrane Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Xbrane Biopharma's historical news coverage. Xbrane Biopharma's after-hype downside and upside margins for the prediction period are 0.01 and 6.68, respectively. We have considered Xbrane Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Xbrane Biopharma is out of control at this time. Analysis and calculation of next after-hype price of Xbrane Biopharma is based on 3 months time horizon.
Xbrane Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Xbrane Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xbrane Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Xbrane Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.48 | 6.50 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.18 | 0.18 | 0.00 |
|
Xbrane Biopharma Hype Timeline
Xbrane Biopharma is at this time traded for 0.18on Stockholm Exchange of Sweden. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Xbrane is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at 0.48%. %. The volatility of related hype on Xbrane Biopharma is about 0.0%, with the expected price after the next announcement by competition of 0.18. About 35.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 7.14. Xbrane Biopharma had not issued any dividends in recent years. Assuming the 90 days trading horizon the next projected press release will be any time. Check out Xbrane Biopharma Basic Forecasting Models to cross-verify your projections.Xbrane Biopharma Related Hype Analysis
Having access to credible news sources related to Xbrane Biopharma's direct competition is more important than ever and may enhance your ability to predict Xbrane Biopharma's future price movements. Getting to know how Xbrane Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Xbrane Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| HNSA | Hansa Biopharma AB | 0.00 | 0 per month | 0.00 | (0.24) | 3.40 | (5.68) | 21.12 | |
| VICO | Vicore Pharma Holding | 0.00 | 0 per month | 0.00 | (0.13) | 3.39 | (4.36) | 52.59 | |
| XSPRAY | XSpray Pharma AB | 0.00 | 0 per month | 0.00 | (0.10) | 5.26 | (3.68) | 25.50 | |
| SANION | Saniona AB | 0.00 | 0 per month | 6.49 | 0.08 | 5.93 | (7.01) | 72.42 |
Xbrane Biopharma Additional Predictive Modules
Most predictive techniques to examine Xbrane price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Xbrane using various technical indicators. When you analyze Xbrane charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Xbrane Biopharma Predictive Indicators
The successful prediction of Xbrane Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Xbrane Biopharma AB, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Xbrane Biopharma based on analysis of Xbrane Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Xbrane Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Xbrane Biopharma's related companies.
Story Coverage note for Xbrane Biopharma
The number of cover stories for Xbrane Biopharma depends on current market conditions and Xbrane Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Xbrane Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Xbrane Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Xbrane Biopharma Short Properties
Xbrane Biopharma's future price predictability will typically decrease when Xbrane Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Xbrane Biopharma AB often depends not only on the future outlook of the potential Xbrane Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Xbrane Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.6 M | |
| Cash And Short Term Investments | 295.2 M |
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |